Attana and Linnaeus University have published the first part of the science behind immunity profiles
In the International Journal of Molecular Science, Attana and Linnaeus University have published the validation of Attana's QCM technology for IgG detection and determination for in-vitro diagnostics. The technique has been validated against electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). The results in this publication are an important part in the development of Attana's immunity profiles.
In the publication Quartz Crystal Microbalance Platform for SARS-CoV-2 Immuno-Diagnostics, Attana's QCM technology has been evaluated for reproducibility, sensitivity, linearity, and specificity for detection of SARS-CoV-2 antibody binding. The results have been compared with ECLIA and CLIA. A total of 119 human serum samples were compared, of which 59 were positive with ECLIA, 52 with CLIA and 48 with QCM. In conclusion, the QCM-based SARS-CoV-2 IgG immunoassay showed high reproducibility and linearity, as well as good coherence with the reference methods.
Factors that affect the results are partly experiment-dependent and partly interaction-dependent. Experiment dependence is, for example, that the different techniques used different types of antigens, QCM S-antigen, ECLIA N-antigen and CLIA S- and N-antigen and different incubation times. QCM measures in real time for two minutes (but has no direct incubation time), ECLIA has nine minutes incubation time and CLIA has a two-step incubation totaling 45 minutes including rinse step.
Interaction dependence is linked to biological properties such as the kinetics of the antibody-antigen interaction and the antibody titer. A low titer and fast association and dissociation rate will initially give higher signal than a low titer with slow kinetics. One of the advantages of real-time measurement in QCM is precisely that the kinetics are determined and thereby can provide additional diagnostic information, i.e. about the neutralizing capacity of the antibodies. Since the purpose of this article was to validate Attana's QCM technique against existing techniques, the kinetics are not included in the results, but they will be in a further publication.
In summary, this has laid the foundation for the current joint project led by Prof. Ian Nicholls at Linnaeus University which aims to develop immunity profiles for more pathogens.
Related Publications:
https://www.nature.com/articles/s41467-020-20251-8
https://europepmc.org/article/med/29399414
https://www.nature.com/articles/s41467-023-42408-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457302/
https://www.frontiersin.org/articles/10.3389/fvets.2023.1243853/full
For more information, please contact:
Marcus Söderberg
CEO Attana AB
ir@attana.com
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: